Equities

4Dmedical Ltd

4Dmedical Ltd

Actions
Health CareMedical Equipment and Services
  • Price (AUD)0.51
  • Today's Change0.03 / 6.25%
  • Shares traded1.60m
  • 1 Year change-22.14%
  • Beta1.9362
Data delayed at least 20 minutes, as of Nov 19 2024 05:10 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

4DMedical Limited is an Australia-based medical technology company. Through its flagship patented XV Technology, the Company enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers its FDA-cleared XV Lung Ventilation Analysis Software (XV LVA), which is a modality to dynamically quantify ventilation throughout the lungs, and its Computed Tomography-enabled counterpart software, CT LVAS. XV LVAS and CT LVAS reports are prepared using the Company’s software as a service (SaaS) delivery model using existing hospital imaging equipment or the Company's XV Scanner. It initiated the commercial rollout of XV LVAS with I-MED Radiology Network (I-MED), which is a diagnostic imaging provider with approximately 250 clinics nationwide. The Company provides its lung imaging technology to other selected clinics across the I-MED network.

  • Revenue in AUD (TTM)3.75m
  • Net income in AUD-35.98m
  • Incorporated2012
  • Employees--
  • Location
    4Dmedical LtdLevel 7 Melbourne Connect700 Swanston StreetMELBOURNE 3053AustraliaAUS
  • Phone+61 39545-5940
  • Websitehttps://4dmedical.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
4DX:ASX since
announced
Transaction
value
Imbio LLCDeal completed11 Dec 202311 Dec 2023Deal completed-46.32%69.30m
Data delayed at least 20 minutes, as of Nov 19 2024 05:10 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
ImpediMed Ltd10.32m-19.79m109.27m83.00--2.68--10.59-0.0098-0.00980.00510.02010.17831.674.28124,325.30-34.20-44.56-37.62-51.7887.2783.08-191.78-220.516.16--0.0273---9.0419.953.56--6.90--
Respiri Ltd1.04m-7.13m112.31m2.00--37.83--108.15-0.007-0.0070.0010.00230.22160.0026.91---152.14-153.06-384.52-255.3469.98---686.48-617.730.3744-108.650.0423--56.850.1379-23.44------
SDI Ltd111.21m10.42m122.43m300.0011.751.308.381.100.08770.08770.93560.79060.81181.555.51--7.617.139.328.4062.0859.869.378.191.408.010.208746.683.116.9247.697.2911.964.72
Optiscan Imaging Ltd1.16m-6.06m139.92m8.00--10.09--121.08-0.0074-0.00740.00140.01660.11380.30620.9086---59.70-49.52-70.78-58.8454.4616.53-524.45-312.657.45--0.0157---31.221.91-39.27--80.89--
EchoIQ Ltd44.50k-5.41m144.19m----19.46--3,240.17-0.0109-0.01090.000090.01260.0048--0.1208---58.04-65.22-76.45-83.27-----12,155.39-1,722.30----0.00---58.54-44.2334.56------
Orthocell Ltd6.76m-7.18m150.64m----29.10--22.27-0.0356-0.03560.03350.02170.24061.479.37---25.55-28.99-30.96-34.0275.9571.10-106.16-242.964.11--0.1321--32.7947.88-14.93--20.63--
Cyclopharm Limited29.04m-9.32m152.26m87.00--3.20--5.24-0.0976-0.09760.30660.42780.51211.114.01333,756.60-16.43-12.60-19.97-14.9464.7770.20-32.08-25.473.42-37.570.1049--11.2215.5028.90---7.83-12.94
Genetic Signatures Ltd14.27m-17.86m161.08m----2.50--11.29-0.1124-0.11240.08640.28380.24531.023.20---30.70-11.57-34.00-12.6944.5655.89-125.15-25.418.76-509.340.0196---35.2914.72-27.11--50.98--
Medadvisor Ltd122.11m792.13k162.64m100.00194.083.1532.611.330.00150.00150.22280.09371.25--11.12--0.8137-15.721.37-24.6060.8159.350.6487-15.38--1.520.1964--24.6467.75107.01--77.57--
EMvision Medical Devices Ltd11.56m-2.73m165.05m----8.90--14.28-0.033-0.0330.14370.21680.6515-------15.38-47.89-20.97-59.47-----23.61-100.24---16.560.1354--62.9959.0629.48------
4DMedical Ltd3.75m-35.98m197.37m----2.78--52.57-0.0972-0.09720.01010.17280.03530.28570.5844---33.79-39.81-41.36-50.9093.6967.64-958.34-1,941.161.74--0.0673--422.4640.12-14.36---1.77--
Anteris Technologies Ltd7.14m-87.90m206.75m1.00--33.10--28.96-5.04-5.040.41220.29550.23613.235.01---304.00-120.86-529.47-189.2768.4366.40-1,287.57-316.850.9233-132.480.3869--4.48-22.85-51.86--42.27--
Aroa Biosurgery Ltd62.66m-9.64m217.29m261.00--2.52--3.47-0.028-0.0280.18230.25030.6071.562.82---9.34-10.37-10.11-12.5285.3980.63-15.39-20.316.40--0.0726--9.0124.26-2,583.84--33.65--
Imricor Medical Systems Inc1.28m-31.36m222.90m--------174.70-0.184-0.1840.0072-0.04910.10410.85013.78---255.91-93.47-387.91-106.30-110.81-134.71-2,458.30-2,462.890.799-4.554.73---24.56-9.29-30.36---10.82--
Data as of Nov 19 2024. Currency figures normalised to 4Dmedical Ltd's reporting currency: Australian Dollar AUD

Institutional shareholders

0.24%Per cent of shares held by top holders
HolderShares% Held
BetaShares Capital Ltd.as of 31 Oct 2024708.93k0.17%
DFA Australia Ltd.as of 30 Sep 2024170.82k0.04%
Dimensional Fund Advisors LPas of 07 Nov 2024111.91k0.03%
Data from 30 Sep 2024 - 14 Nov 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.